AAH clarifies defence
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.BY MAGNUS GRIMOND
AAH, the pharmaceuticals group fending off a £400m bid from the German group Gehe, has been forced to clarify its latest defence document after criticism by the Takeover Panel.
The Panel has forced AAH to admit it had no hard evidence that Gehe would continue to support the share price by buying shares if its offer lapsed. Under takeover rules Gehe would not be allowed to increase its stake by more than 1 per cent until 12 months after a failed bid. AAH had suggested to shareholders that Gehe would then seek to increase its holding and the prospect would "further underpin the value of your shares."
Gehe now owns or has acceptances for 28 per cent of AAH. The final deadline for the offer is next Tuesday, May 2 ; several large institutions hold close to a third of the equity.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments